摘要
目的:系统评价止嗽散治疗慢性支气管炎的临床疗效。方法:计算机检索维普、万方、中国知识资源总库及PubMed数据库,时间限定为建库至2019年5月,筛选以止嗽散为主方治疗慢性支气管炎的临床随机对照试验(RCTs),由2名研究者独立对文献进行筛选及数据提取,使用Cochrane系统评价手册对筛选的文献进行偏倚风险质量评价,使用Revman5.3软件进行Meta分析。结果:共纳入12篇文献,观察组570例,对照组518例,共计1088名患者,Meta分析结果显示,止嗽散或联合西药治疗慢性支气管炎总有效率OR=5.31,95%CI[3.63,7.77],P<0.00001,止嗽散联合西药治疗慢性支气管炎治愈率OR=2.28,95%CI[1.57,3.32],P<0.0001,差异有统计学意义。结论:止嗽散治疗慢性支气管炎疗效确切,但由于纳入研究的总体质量水平不高,存在一定的偏倚,仍然需要更多的RCTs来评价其临床疗效。
Objective:To systematically evaluate the clinical efficacy of the Zhisou powder(止嗽散)on chronic bronchitis.Methods:We collected randomized controlled trials(RCTs)of the Zhisou powder on chronic bronchitis from VIP database,Wanfang database,CNKI and PubMed by computer retrieval.The time is limited to the construction of the library until May 2019.The literature was screened and extracted by two independent researchers.The bias risk quality of selected literature was evaluated with the Cochrane Reviewer’s Handbook for systematic review,and Revman 5.3 software was adopted to perform Meta-analysis.Results:A total 26 RCTs were enrolled,including 1088 patients,570 patients in the observation group and 518 patients in the control group.Meta-analysis results show that total efficacy of the Zhisou powder or combined western medicine on chronic bronchitis:OR=5.31,95%CI[3.63,7.77],P<0.00001,cure rate:OR=2.28,95%CI[1.57,3.32],P<0.0001,and the difference was statistically significant.Conclusion:The efficacy of the Zhisou powder on chronic bronchitis is exact.Due to the low overall quality level of the included studies,there is a certain bias,and more rigorously designed,high-quality,multi-center,large-sample RCTs are needed to further validate the clinical efficacy.
出处
《中医临床研究》
2020年第17期144-148,共5页
Clinical Journal Of Chinese Medicine
基金
国家自然科学基金(81760802)
广西自然科学基金(2016GXNSFAA380133)。
